CERVAVAC

Cervavac is a vaccine used to protect against certain types of human papillomavirus (HPV), which can lead to cervical cancer and other HPV-related diseases. Its a (Human Papillomavirus 4-valent Vaccine, Recombinant) Suspension for intramuscular injection produced from strain: Hansenula polymorpha

Indications:

Cervavac is a vaccine indicated in both girls and women and boys and men from  9 through 26 years of age for the prevention of the following diseases caused by HPV virus strains-16 and 18. & 6 and 11. :

• Cervical, vulvar, vaginal, anal, oropharyngeal and other head and

neck cancers, Genital warts (condyloma acuminata),precancerous or dysplastic lesions, Cervical intraepithelial neoplasia (CIN) grade 2/3 and cervical

adenocarcinoma in situ (AIS). Cervical intraepithelial neoplasia (CIN) grade 1, Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3,Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3,Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3.

Vaccination does not eliminate the necessity for women to continue to undergo recommended

cervical cancer screening. Women who receive Cervavac should continue to undergo cervical cancer screening per standard of care.

• Recipients of Cervavac should not discontinue anal cancer screening if it has been

recommended by a healthcare provider.

• Cervavac has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a person has previously been exposed through sexual activity

How It Works

Cervavac targets nine HPV types, including those most commonly associated with cervical, vaginal, vulvar, and anal cancers, as well as genital warts.HPV only infects human beings. The efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Efficacy of Cervavac against anogenital diseases related to the vaccine HPV types in human beings is thought to be mediated by humoral immune responses induced by the vaccine, although the exact mechanism of protection is unknown.

Administration, Dosage, Schedule:

• Given as a series of two or three injections over six months.
• Recommended for age 9 and through age 26.
• Age Regimen Schedule:
• 9 through 14 years

 2-dose 0, 6 to 12 months

• 15 through 26 years

  3-dose 0, 2, 6 months

The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period.

To be administered in the deltoid or anterolateral area of the thigh.

Side Effects

Common side effects may include:

• Pain or swelling at the injection site
• Fever
• Headache
• Dizziness

Severe reactions are rare.

Pregnancy and Lactation

• Pregnancy: Not recommended during pregnancy. Women should inform their healthcare provider if they are or may become pregnant.
• Lactation: Generally considered safe, but discuss with a healthcare provider.

Minimum Age Group

• Minimum Age: Approved for use for girls and women 9yrs through 26yrs.Approved for use for  boys and men 9yrs through 26 years of age 

Contraindications

• Allergic Reactions: Not for individuals with severe allergies to yeast or any vaccine component.
• Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids

Cervavac is an important tool in preventing HPV-related cancers and conditions. It's most effective when given before exposure to HPV through sexual contact. Always consult healthcare providers for personalized advice.